Business
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
- Highly statistically significant and clinically meaningful results - - 63% mean blood Phe reduction in primary analysis population
About this update from Ptc Therapeutics, Inc.
[{"type":"text","content":"- Highly statistically significant and clinically meaningful results - \n- 63% mean blood Phe reduction in primary analysis population (p","length":206,"tagName":"div"}]